Table 2 Clinical features of patients following division into groups according to DKK-1 serum levels (low vs. high)
From: High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients
Low DKK-1 (n = 40) | High DKK-1 (n = 40) | ||||
|---|---|---|---|---|---|
Mean ± SD | Median | Mean ± SD | Median | p-Value | |
DKK-1 (pmol/l) | 16.18 ± 7.5 | 14.69 | 38.44 ± 7.24 | 38.07 | <0.01 |
Follow up (years) | 8.56 ± 2.77 | 8.28 | 8.26 ± 3.29 | 8.9 | n.s. |
Age (years) | 65.03 ± 4.40 | 64.99 | 65.27 ± 5.66 | 64.98 | n.s. |
PSA (ng/ml) | 14.35 ± 13.27 | 8.88 | 9.86 ± 8.98 | 7.21 | n.s. |
n (%) | n (%) | p-Value | |||
Tumour staging | n.s. | ||||
pT2 | 17 (21.3%) | 18 (22.5%) | |||
pT3/4 | 23 (28.8%) | 22 (27.5%) | |||
Gleason score | n.s. | ||||
< 7 | 15 (18.8%) | 15 (18.8%) | |||
= 7 | 14 (17.5%) | 12 (15.0%) | |||
> 7 | 11 (13.8%) | 13 (16.3%) | |||